Halobetasol and Natalizumab interaction
Halobetasol and Natalizumab: the Natalizumab prescribing label describes an interaction that usually calls for monitoring, a dose change, or spacing the doses.
Usually manageable with monitoring or a dose change. Tell your pharmacist you take both.
What the FDA labels say
From the Natalizumab (TYRUKO) label · effective 2025-10-31
In Studies MS1 and MS2, an increase in infections was seen in patients concurrently receiving short courses of corticosteroids.
However, the increase in infections in natalizumab-treated patients who received steroids was similar to the increase in placebo-treated patients who received steroids.
In Studies CD1 and CD2, an increase in infections was seen in patients concurrently receiving corticosteroids.
However, the increase in infections was similar in placebo-treated and natalizumab-treated patients who received steroids.
…receiving natalizumab products should not be treated with concomitant immunosuppressants (e.g., 6‑ mercaptopurine, azathioprine, cyclosporine, or methotrexate) or inhibitors of TNF-α, and corticosteroids should be tapered in those patients with Crohn’s disease who are on chronic corticosteroids when they start TYRUKO therapy [see Indications and Usage ( 1.2 ) and Warnings…
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.